Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 May 21;16(5):e0250844. doi: 10.1371/journal.pone.0250844

Patterns of mobility and its impact on retention in care among people living with HIV in the Manhiça District, Mozambique

Edson L Bernardo 1,2, Tacilta Nhampossa 2,3, Kate Clouse 1,4, James G Carlucci 1,5, Sheila Fernández-Luis 2,6, Laura Fuente-Soro 2,6, Ariel Nhacolo 2, Mohsin Sidat 7, Denise Naniche 2,6, Troy D Moon 1,5,*
Editor: Matt A Price8
PMCID: PMC8139482  PMID: 34019556

Abstract

Introduction

Retention in HIV care is a challenge in Mozambique. Mozambique´s southern provinces have the highest mobility levels of the country. Mobility may result in poorer response to HIV care and treatment initiatives.

Methods

We conducted a cross-sectional survey to explore the impact of mobility on retention for HIV-positive adults on ART presenting to the clinic in December 2017 and January 2018. Survey data were linked to participant clinical records from the HIV care and treatment program. This study took place in Manhiça District, southern Mozambique. We enrolled self-identified migrants (moved outside of Manhiça District ≤12 months prior to survey) and non-migrants, matched by age and sex.

Results

390 HIV-positive adults were included. We found frequent movement: 45% of migrants reported leaving the district 3–5 times over the past 12 months, usually for extended stays. South Africa was the most common destination (71%). Overall, 30% of participants had at least one delay (15–60 days) in ART pick-up and 11% were delayed >60 days, though no significant difference was seen between mobile and non-mobile cohorts. Few migrants accessed care while traveling.

Conclusion

Our population of mobile and non-mobile participants showed frequent lapses in ART pick-up. Mobility could be for extended time periods and HIV care frequently did not continue at the destination. Studies are needed to evaluate the impact of Mozambique´s approach of providing 3-months ART among mobile populations and barriers to care while traveling, as is better education on how and where to access care when traveling.

Introduction

Retention in HIV care and treatment continues to be a significant challenge in Mozambique since the inception of its HIV programs in the early 2000s [16]. Mozambique is one of the countries most affected by HIV with a prevalence of 13.2% in 2015 and 1.2 million persons receiving antiretroviral therapy (ART) as of December 2017 [17]. Significant efforts have been made to address the HIV epidemic in Mozambique, yet as of March 2019 only 49% of persons living with HIV (PLHIV) were receiving ART and only 77% of those on treatment had undetectable viral loads [8].

Retention in care and treatment is essential to maintaining good adherence to ART and ensuring optimal treatment outcomes [9]. Various studies have identified barriers to HIV retention in Mozambique, including medication side effects, complexity of dosing schedules, low patient education level, poverty, stigma, distance and transportation challenges, quality of care received, and reliance on traditional medicines [2,5,10,11]. Mozambique´s continued low retention threatens to undo the gains made in terms of HIV testing and enrollment over the last several years [12].

One potential challenge to retention in HIV care and treatment that is gaining attention is the mobility of people between regions and countries [1317]. In 2011, UNAIDS and the International Organization for Migration (IOM), signed an agreement recognizing HIV-related challenges faced by mobile populations [18]. Their objective was to integrate human rights and the needs of mobile populations into national and regional HIV responses and to ensure universal access to HIV prevention, treatment, care and support [18].

Recent studies have shown that the mobility of PLHIV can create potential vulnerabilities for the spread of new HIV infections and may result in poorer response to HIV care and treatment initiatives, leading to an overall negative impact on the health and economic status of this population [16,19,20]. One study in Lesotho, looking at barriers to access of PLHIV migrating to South Africa, found that roughly 25% had defaulted on their treatment, with the primary reason reported as a failure to get back to Lesotho to collect their medications due to fears that treatment received in South Africa would be “stronger” and “have more side effects” [20].

The southern provinces of Mozambique have some of the highest mobility levels of the country. This region borders both South Africa and Eswatini and features two high-traffic transport corridors which link Maputo with these two countries. Studies conducted in 2012 showed that these transport corridors had high levels of commercial sex work and that high-risk sexual practices were common along these routes [21]. To date, there have been no studies specifically describing the implications of mobility on HIV care in Mozambique.

We sought to describe the patterns of mobility among PLHIV seeking care at the Manhiça District Hospital (MDH) in southern Mozambique and the potential impact on engagement in HIV care. Results from this analysis may be of importance to Mozambique and other countries in the region with large migratory populations as they strive to improve effectiveness of HIV care and treatment service approaches to this population.

Materials and methods

Setting

This study was conducted at the Manhiça Health Research Center (Centro de Investigação de Saúde de Manhiça, CISM) at MDH of Manhiça District, Mozambique [22]. At the time of the study, the district population was served by MDH, one rural hospital and 18 peripheral health posts. HIV services included HIV care and treatment clinics, HIV counseling and testing, as well as prevention of mother-to-child transmission (PMTCT) services. As of 2016, Mozambique had implemented “test and treat” strategies for same-day initiation of ART once someone is identified as being HIV-positive [23].

Manhiça District is a rural district located in southern Mozambique, whose catchment area has a high prevalence of both tuberculosis (TB) and HIV infection. Agriculture and subsistence farming predominate, but large portions of the population engage in seasonal migration to South Africa, seeking work in the mines. A strength of Manhiça District is that more than half of the population (approximately 210,000 inhabitants) participates in a continuous health and demographic surveillance system (HDSS), carried out by CISM [24]. The HDSS collects data on all vital events such as births, deaths, pregnancies and mobility patterns for those registered in the system [2527].

Study design and participants

We conducted a cross-sectional survey to collect demographic information and mobility history, including whether migration was international or domestic, rural or urban, the duration of travel, pattern of home returns, whether children accompanied the travel, healthcare access while at their destination, and self-reported adherence to ART. Consecutive patients, ≥18 years old, presenting for their scheduled HIV clinic visit at MDH from December 01, 2017 to January 31, 2018 were invited to participate. These months were chosen due to the fact they are holiday months in which many migrating patients return to Manhiça. Patients were first approached for inclusion in this study if they were residents of the District of Manhiça, had migrated out of the district in the 12 months prior to study enrollment, and had initiated ART prior to study enrollment. For each person enrolled with a history of migration, an age (± 5 years)- and sex-matched person without a history of migration, and who attended the HIV clinic was invited to participate. Controls were selected through convenience sampling from a list of patients seen at the clinic within the seven-day period following recruitment of the patient with a history of migration. As this study recruited participants from a single district in which migratory patterns historically predominated to South Africa, our results may not be representative of migratory HIV-infected adults residing elsewhere in Mozambique or the region.

Data collection and management

Patients attending routine scheduled visits for HIV care were screened for eligibility by a project-dedicated health assistant after completion of their routine clinic visit. Surveys were administered face-to-face in the preferred language of the participant, either Portuguese or a local language (Changana). Survey responses were translated in real-time by the interviewer and recorded electronically in Portuguese via a tablet utilizing Open Data Kit software 1.4 (ODK) [28]. Data were then uploaded into Research Electronic Data Capture (REDCap), a secure web-based application designed to support data capture for research studies [29]. Data were then linked with the patient´s clinical information registered within the HIV programs electronic patient tracking system (ePTS), including sociodemographic variables, clinical history, and pharmacy/ART pick-up data.

Definitions utilized

Individuals were identified as mobile if they answered “yes” to the survey question “Have you moved outside of Manhiça District in the 12 months prior to survey implementation?”. Per national protocols at the time of the study, HIV patients seen at MDH were typically dispensed a 30-day supply of their ART and other HIV medications. While clinic visit schedules could be spaced out on an every 1-month, 3-month, or 6-month basis depending on the needs of the individual, generally the patient, or a designated representative, had to return to the clinic once a month for pharmacy refills.

For our outcome of interest, patients were defined as “retained in care”, if they had no missed clinic visits or pharmacy pick-ups of >15 days during the 12-months prior to survey implementation. If the patient had at least one delay of between 15–60 days in picking up their ART, they were defined as “delayed ART pick-up”. If the patient had a least one delay of >60 days in their ART pick-up they were defined as “lost-to-follow-up”, regardless of the fact that they all were back in care at the time of completing the survey. These definitions are the official definitions used by the Mozambican Ministry of Health to assess patient retention in HIV care and treatment programs.

Statistical analysis

Participant recruitment was conducted in the months of December and January and based on prior clinic visit volumes it was anticipated that MDH would see approximately 100 daily patient visits during this time frame in the HIV care and treatment program and that 20% of these visits would meet eligibility criteria as a participant with history of migration out of the district (~15 patients per day or a total of 150 mobile participants). As our estimated recruitment sample was fixed (based on convenience), the statistical power to detect a difference in LTFU was variable depending on actual LTFU rates in each group (i.e. for a LTFU of 20% in the non-mobile group, we would expect a 96% power to detect a difference if the LTFU was 40% in the migrant group, but only a 46% power to detect a difference if the LTFU was 30% in the migrant group).

Data were analyzed using Stata version 15.1. Descriptive statistics were used to summarize the data, using frequency distribution tables. Associations between categorical variables were tested using Chi-square or Fisher’s exact tests. A p-value of less than 0.05 was considered statistically significant.

Ethical considerations

This study received ethical approval from the Institutional Committee for Bioethics in Health of CISM (CIBS-CISM/169/2017) and from Vanderbilt University Institutional Review Board (#200328). Written informed consent was provided by all participants and approvals were obtained from the Provincial Directorate of Health.

Results

A total of 390 mobile and non-mobile HIV-positive adults on ART were included in this study. The majority (72%) were 25–44 years old and 57% were male. Two-thirds (66%) of participants were married. Only 19% had formal education beyond primary school. The majority (87%) were employed, with a significantly higher proportion of employment being reported in our mobile population than the non-mobile population (98% vs. 78% respectively, p<0.001). Overall, 95% of participants reported ownership of a cellphone. Seventy-seven percent reported being on ART for 1–5 years. Most (66%) were WHO clinical stage I at the time of survey administration. Finally, 76% of our study population had disclosed their HIV status to their partner or family (Table 1).

Table 1. Sociodemographic characteristics of mobile and non-mobile HIV-positive adults enrolled in HIV care and treatment at Manhiça District Hospital.

N = 390 Mobile n (%) Non-mobile n (%) Total n (%) p-value*
Total 195 (50) 195 (50) 390 (100) --
Age (n = 389)
    18–24 4 (2) 10 (5) 14 (4) 0.571
    25–34 59 (30) 54 (28) 113 (29)
    35–44 84 (43) 86 (44) 170 (43)
    45–54 32 (18) 33 (17) 69 (18)
    ≥55 12 (6) 11 (6) 23 (6)
Gender
    Male 116 (59) 108 (55) 224 (57) 0.671
    Female 79 (40) 87 (45) 166 (43)
Marital status
    Married 129 (66) 129 (66) 258 (66) 0.041
    Widowed 14 (7) 27 (14) 41 (11)
    Divorced/Separated 25 (13) 25 (13) 50 (13)
    Single/Never Married 27 (14) 14 (7) 41 (11)
Education
    No education 18 (9) 32 (16) 50 (13) 0.012
    Grade 7 or less 140 (72) 126 (65) 266 (68)
    Completed High school 36 (19) 29 (15) 65 (17)
    Some College 1 (<1) 8 (4) 9 (2)
Religion
    Catholic 88 (45) 93 (48) 181 (46) 0.764
    Protestant Christian 40 (21) 43 (22) 83 (21)
    Islamic 6 (3) 5 (3) 11 (3)
    Zion 53 (27) 47 (24) 100 (26)
    Other 8 (4) 7 (4) 15 (4)
Employment (n = 343)
    No 3 (2) 42 (22) 45 (13) <0.001
    Yes 145 (98) 153 (78) 298 (87)
Type of employment (n = 298)
    Administrative 6 (4) 17 (11) 23 (8) <0.001
    Agriculture 8 (6) 15 (10) 23 (8)
    Self-employed (non-farming) 26 (18) 39 (25) 65 (22)
    Industry/Mining 18 (12) 10 (7) 28 (9)
    Domestic work 12 (8) 27 (18) 39 (13)
    Construction 23 (16) 14 (9) 37 (12)
    Other 53 (36) 30 (20) 83 (28)
Owns cellphone (n = 389)
    Yes 191 (98) 177 (91) 368 (95) 0.003
    No 4 (2) 17 (9) 21 (5)
Time since HIV diagnosis
    Less than 3 months 2 (1) 1 (1) 3 (1) 0.450
    3 to 12 months 12 (6) 7 (4) 19 (5)
    1 to 5 years 149 (76) 146 (75) 295 (76)
    More than 5 years 32 (16) 41 (21) 73 (19)
Duration on ART (n = 389) 0.425
    Less than 3 months 2 (1) 1 (1) 3 (1)
    3 to 12 months 14 (7) 8 (4) 22 (6)
    1 to 5 years 149 (77) 149 (76) 298 (77)
    More than 5 years 29 (15) 37 (19) 66 (17)
WHO stage at diagnosis (n = 357)
    I 117 (66) 117 (65) 234 (66) 0.1384
    II 26 (15) 29 (16) 55 (15)
    III 28 (16) 28 (16) 56 (16)
    IV 6 (3) 6 (3) 12 (3)
HIV status disclosed to partner
    Yes 152 (78) 145 (74) 297 (76) <0.001
    No 17 (9) 36 (18) 53 (14)
    Not applicable (no partner) 26 (13) 0 (0) 26 (7)
    Refused to answer 0 (0) 14 (7) 14 (4)

*Chi-square or Fisher’s exact tests.

ART = antiretroviral therapy.

Among mobile study participants, 68% reported leaving the district 2–5 times over the 12-month period prior to survey administration, with 38% reporting they were away 15 days to 3 months each trip, and another 25% reporting they were away 3–9 months each trip (Table 2). Nearly 80% reported their migration destination as being an urban setting. For those who were mobile within Mozambique, roughly 83% stayed in the southern region, migrating to either the capital city of Maputo (45%) or its surrounding areas within Maputo Province (15%) or Gaza Province (23%), all within a 1-2-hour drive of Maputo. For those reporting migrating to a location outside of Mozambique, 97% reported South Africa as the country of destination. Seventy-six percent of participants reported work as the reason for travel, with another 14% reporting they were seeking better life opportunities.

Table 2. Migration patterns and characteristics of mobile HIV-infected adults enrolled in HIV care and treatment at Manhiça District Hospital.

N = 195 n (%)
Number of times left district (over the last 12 months)
    Once 18 (9)
    2 times 48 (25)
    3–5 times 84 (43)
    Once a month 18 (9)
    Once a week 6 (3)
    Other 5 (3)
    Don’t know 16 (8)
Typical length of time at destination of travel
    Less than a week 27 (14)
    Less than 15 days 25 (13)
    From 15 days to 3 months 75 (38)
    From 3 to 9 months 49 (25)
    More than 9 months 15 (8)
    Don’t Know 4 (2)
Where traveled to?
    Rural 37 (19)
    Urban 155 (79)
    Both 3 (2)
Which province (if within Mozambique) (n = 63)
    Maputo City 24 (38)
    Maputo Province 8 (12)
    Gaza 12 (19)
    Inhambane 1 (2)
    Sofala 1 (2)
    Nampula 3 (5)
    Tete 3 (5)
    Don’t know 11 (17)
Which country (if outside Mozambique) (n = 132)
    South Africa 128 (97)
    Botswana 3 (2)
    Democratic Republic of Congo 1 (1)
Reason for traveling (n = 193)
    Work 147 (76)
    Death in Family 2 (1)
    Looking for better life opportunities 27 (14)
    Following Partner 10 (5)
    Others 7 (4)
What kind of job at destination? (n = 148)
    Administrative 6 (4)
    Agriculture 8 (5)
    Self Employed 26 (18)
    Industry/Mining 18 (12)
    Domestic Work 12 (8)
    Unemployed 3 (2)
    Other 75 (51)
Access to ART at destination
    Yes 133 (68)
    No 62 (31)
Reason for no access to ART at destination (n = 62)
    Didn’t look for it 16 (26)
    Didn’t know could pick up at destination 1 (2)
    Denied follow-up at clinic 1 (2)
    No ART stock 2 (3)
    Other 42 (68)
How accessed ART when at destination (n = 133)
    Sent by family member 82 (62)
    Local pharmacy 1 (<1)
    Took enough with them from Manhiça 49 (37)
    Other 1 (1)
Frequency of HIV care follow-up at destination
    Monthly 3 (1)
    Every 2 months 1 (<1)
    Every 6 months 1 (<1)
    No follow-up 190 (97)
Frequency of HIV care follow-up (at MDH) after traveling?
    Monthly 59 (30)
    Every 2 months 16 (8)
    Every 3 months 66 (34)
    Every 6 months 51 (26)
    Once a year 1 (<1)
    No follow-up 2 (1)

ART = antiretroviral therapy.

Overall, only 68% of our mobile population reported that they had access to ART when traveling. When questioned as to the reason for no access to ART, 26% said they did not look for places within their destination location to receive ART, while 68% responded “other” without further explanation as to the reason. Further, 62% of participants reported that a family member brought them their ART when they were traveling and another 37% reported they took enough ART with them to last the length of their trip. Additionally, 98% of our mobile population reported they did not seek HIV care at their site of dislocation. We then asked how frequently our mobile population was able to maintain clinic visits (regardless of what was scheduled) at MDH during their travel periods. The most common response was every three months (34%), followed by monthly (30%) and then every six months (26%).

In order to understand if there were any differences for migrants within Mozambique versus those who migrate outside the country, we asked questions on self-reported perceived challenges in accessing HIV care (Table 3). No statistically significant difference was seen between the two groups in relation to their responses, however important challenges for our cohort as a whole were identified. When we asked about challenges in accessing HIV care upon their return to Manhiça District, the majority (~90%) reported no challenges. However, roughly 8% reported that “long wait times at the clinic” was a barrier to accessing care upon their return. We then asked about alternative ART dosing schedules that could help facilitate their adherence to their medications. Most (64%), stated they would prefer a >3-month dosing schedule, followed by a 3-month dosing schedule (33%). Twenty-seven percent of participants who migrate out of the country stated they had a relationship partner at their destination location, compared to only 19% for those migrating within Mozambique, though this was not statistically significant. Finally, approximately 15% of our mobile population reported they had children at their destination location, regardless if within Mozambique or not.

Table 3. Self-reported perceptions of mobile HIV-positive adults about their HIV care by those who migrate within Mozambique versus outside of Mozambique.

N = 185 In-country n (%) Other Country n (%) Total n (%) P-value
Total 53 (29) 132 (71) 185 (100) --
Difficulties in ART care when returning to MDH (n = 185)
    Long wait time at clinic 4 (8) 11 (8) 15 (8) 1.000
    Bad service 0 (0) 2 (1.5) 2 (1)
    No difficulty found 49 (92) 117 (89) 166 (90)
    Other 0 (0) 2 (1.5) 2 (1)
Preferred dosing schedule when traveling (n = 183)
    3-month supply 16 (31) 45 (34) 61 (33) 0.855
    3 to 6-month supply 25 (48) 58 (44) 83 (45)
    6-month supply 9 (17) 25 (19) 34 (19)
    Fine with current 1-month supply 2 (4) 3 (2) 5 (3)
Do you have a relationship at destination location? (n = 185)
    Yes 10 (19) 35 (27) 45 (24) 0.273
    No 43 (81) 97 (73) 140 (76)
Do you have children at destination location (n = 185)
    Yes 7 (13) 20 (15) 27 (15) 0.821
    No 46 (87) 112 (85) 158 (85)

*Chi-square of Fisher’s exact tests.

    • MDH = Manhiça District Hospital.

    • We had incomplete response data from 10 mobile participants that were excluded from this analysis.

We explored the participant´s perceptions as to whether they had ever been classified as lost to follow-up since they initiated taking of ART. Overall, 5% of the mobile population responded that they had ever been lost to follow-up, compared to only 1% of our non-mobile population (p = 0.036) (3% of the total population). Next, we analyzed clinical data based on pharmacy pick-up dates for both our mobile and non-mobile participants. Forty-one participants had insufficient pharmacy pick-up data to be included in this analysis. Of the 349 participants that had complete data, 30% had at least one delay (15–60 days late) in ART pick-up documented in the pharmacy records for the 12-month period prior to survey administration, and 11% had at least one documented delay in ART pick-up of >60 days in ART. There was no significant difference in delays noted between our mobile and non-mobile cohorts (Table 4).

Table 4. Comparison of antiretroviral therapy (ART) spacing pick-ups between mobile and non-mobile HIV-infected adults enrolled in HIV care and treatment at Manhiça District Hospital.

N = 349& Mobile n (%) Non-mobile n (%) Total n (%) p-value*
Delayed ART pickups (15–60 days late) 0.114
    Yes 50 (29) 55 (31) 105 (30)
    No 121 (71) 123 (69) 244 (70)
Lost to follow-up (>60 days) 0.091
    Yes 19 (11) 18 (10) 37 (11)
    No 152 (89) 160 (90) 312 (89)

&41 participants did not have sufficiently complete pharmacy pick-up data to have been included in the analysis.

*Chi-square or Fisher’s exact tests.

Discussion

Manhiça District, in southern Mozambique, is a region with high HIV prevalence (~40%) and a large population that migrates to South Africa every year to work in the mines [30]. Furthermore, Mozambique, more broadly, is a country that continues to have challenges with the long-term retention of PLHIV in treatment [16]. As such, we sought to better understand the dynamics of this mobile HIV population and to explore the impact that their mobility has on retention and adherence to HIV care and treatment.

Through purposefully enrolling a mobile population, we found that they were predominantly male and largely of the 25-44-year-old age group, with traveling for work-related reasons being the most commonly cited reason for travel outside of Manhiça District. This younger, male demographic makes up a large proportion of the labor workforce in Africa and is consistent with prior descriptions of cross-border migration for employment within the Southern Africa Development Community (SADC), that has been going on for more than 150 years [3133].

Among the mobile participants in our study, multiple migration events each year were common and often for considerable amounts of time. Two-thirds of the migrant cohort reported that they had traveled outside of the district between 2–5 times over the course of the 12-month period prior to survey implementation and one-quarter (25%) staying away 3–9 months per trip. South Africa was the most common destination location for our cohort of patients, however a quarter of our mobile HIV population had migratory destinations inside of Mozambique, mostly to urban areas within a 1-2-hour drive of Maputo. In recent years, Mozambique´s economy has experienced dynamic growth, mainly as a result of the expansion of extraction industries for coal, natural gas, petroleum, and gemstones [34]. Future studies should be established to better document and understand this in-country migration, including ways to reduce its potential impacts on retention in HIV care and adherence to ART medication.

We found no significant difference between our mobile and non-mobile patients in terms of their likelihood to have been classified as delayed in their ART pharmacy pick-up or as lost-to-follow-up. This is likely due to the fact that actual LTFU rates in each group were lower than what was anticipated pre-study implementation and as a result we may not have been sufficiently powered to detect a difference. Lapses or delays in care were frequent, regardless of migrant status. Among all study participants, pharmacy records showed that 30% had at least one instance over the course of the preceding 12-month period in which they were delayed between 15–60 days, and 11% had been classified as being lost-to-follow-up (delay of >60 days in picking up their ART) at least once, a striking disparity to the 3% of participants who self-perceived they had ever been lost to follow-up. It is unclear whether the lower perceived lost to follow-up by self-report is based on response bias in which the participant responds in the way they feel the interviewer wants them to, or if this is a true lack of awareness as to what good adherence and retention really means. Further exploration of this phenomena is warranted. Furthermore, recruitment into this study was done during routine HIV clinic visits at MDH. Therefore, all participants in this study were somehow engaged in care or had re-entered care if they had previously been classified as being late to a visit or lost. As such, the proportion of our patients classified as “delayed” and “lost-to-follow-up” likely is an underestimation of the true retention for this region, as those who did not return to care are not captured here.

Despite the lack of difference in overall retention of our mobile versus non-mobile HIV patients, there are some notable findings of our mobile population related to their HIV care and treatment that necessitate further exploration. First, even though our mobile population reported frequent migratory events over the course of a year and that each event could last from 15 days to 9 months, there was a nearly universal reported lack of HIV follow-up care at their site of destination. When asked about access to their ART medications at their destination, most respondents reported that they brought enough medications with them or that they had family members bring their ART to them while they were away. Additional research to verify and further explore these findings and other health-seeking behaviors of migrant PLHIV are warranted.

The lack of HIV treatment follow-up while traveling in our cohort, is consistent with a report looking at the challenges faced by migrant populations throughout South Africa, which found that a lack of familiarity with a “foreign” health system; a perception that the South African health system would refuse care to non-citizens; a perception that South African ART is stronger and could have more adverse side effects; and a general preference to seek care when back at their home location, were all reasons listed for not seeking HIV care and treatment while in South Africa [16,20,35]. Our survey was not detailed enough to ascertain whether Mozambique´s migratory population would have similar responses. However, the overwhelming lack of follow-up care at the destination reported in our population highlights an urgent need to better understand this dynamic. Initiatives are needed to help migrants in overcoming the barriers to care and treatment when in a different country and provide education and preparatory guidance prior to one´s travel to ensure they either have what they need, or have a plan for how to get what they need when traveling. Our population´s self-reported perception of preparedness contradicts the pharmacy pick-up records that showed that >40% of our cohort experienced at least some form of delay in receiving their ART over the course of the 12-month period.

Twenty-four percent of our mobile population reported their migration destination to be within Mozambique. The challenges to accessing care described above for South Africa should not be present in another location within Mozambique, yet we found no real differences in responses for those migrating domestically compared to internationally with regards to accessing HIV follow-up care at the destination; accessing ART medications at the destination; or in the proportion of persons with pharmacy pick-up records documenting at least one period of delay in pick-up. This further highlights the need for future research into the barriers of accessing care and for retention in HIV care and treatment for Mozambique´s mobile population.

At the time of survey implementation, Mozambique´s national HIV treatment guidelines called for monthly pharmacy pick-up of ART, despite recent initiatives for spacing-out clinical visits to 3–6 months [36]. Later in 2018, after the current period of study, Mozambique began to allow 3-month dispensing of ART. Similarly, Mozambique could explore allowing patients who are stable, to receive a 6-month supply of their ART medications. The impact of dispensing longer periods of ART on retention in care, has yet to be fully examined but should be included in future studies.

A strength of this study is that we were able to triangulate participant survey data with their HIV pharmacy pick-up records in roughly 90% of participants, thus allowing us to make direct comparisons between actual pharmacy visits and one´s self-reported perceptions of their adherence. However, this also represents a study limitation as 41 participants had incomplete data related to their pharmacy pick-ups. This study also had several other limitations. First, patients were recruited from those attending an HIV clinic visit at MDH. This means that all patients enrolled in this study had either never left care or had returned to care if previously identified as delayed or lost-to-follow-up, thus likely giving an underestimation of the true poor retention of this population. Next, study interviews were conducted only in the months of December and January, based on an assumption that Manhiça’s mobile HIV-infected population would return home during the holidays. This may not be accurate, resulting in our findings not being representative to this population as a whole. For this analysis our clinical data capture was limited to duration of ART treatment, length of time since HIV diagnosis, as well as WHO clinical staging information. We did not have access to other laboratory values that could be important in evaluating the effect of migration on retention in care, such as CD4 count and whether the participant was virally suppressed or not. Finally, we were unable to determine the exact amount of ART given to each patient at each of their pharmacy pick-up visits. At the time of survey implementation, Mozambican protocols limited dispensing of more than a 30-day supply of ART, however in practice there were likely instances where more than a 30-day supply was given, which could make some of our study participants appear delayed or lost-to-follow-up based on visit schedules, when actually they had ART medication on them.

Conclusion

Manhiça’s HIV-positive mobile population frequented locations both within Mozambique and neighboring South Africa, characterized by multiple trips for work and being away for extended periods of time. A large proportion of both our mobile and non-mobile population experienced delays in ART pick-up during the prior 12-month period, despite self-perception of not being delayed. Challenges in accessing HIV care and treatment and decisions around accessing care when traveling were not different if migration was within Mozambique or out. Surprisingly, no difference in LTFU was found between our mobile and non-mobile populations, most likely due to being insufficiently powered to detect a difference based on lower than anticipated actual LTFU rates in each group. Further in-depth research with a larger population into the barriers of accessing care and for retention in HIV care and treatment for Mozambique´s mobile population is needed. Studies evaluating Mozambique´s relatively new initiative at providing 3-month supplies of ART are needed to evaluate its impact on retention and adherence. Alternative ART dosing strategies for this population may need to be for even longer. Finally, better education for mobile populations on how and where to access care when traveling is warranted.

Supporting information

S1 File. Study survey mobile adult english.

(DOCX)

S2 File. Study survey mobile adult portuguese.

(DOCX)

S3 File. Study survey nonmobile adult english.

(DOCX)

S4 File. Study survey nonmobile adult portuguese.

(DOCX)

S5 File. Deidentified data set.

(XLSX)

S6 File. Data dictionary for deidentified data set.

(XLSX)

Acknowledgments

The authors thank all study participants, the healthcare workers from CISM and MDH who assisted with data collection, and the district health authorities for their collaboration.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This research was supported by the Fogarty International Center of the National Institutes of Health under Award Number D43 TW009745, awarded to TM. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Filimão DBC, Moon TD, Senise JF, Diaz RS, Sidat M, Castelo A. Individual factors associated with time to non-adherence to ART pick-up within HIV care and treatment services in three health facilities of Zambézia Province, Mozambique. PLoS One. 2019;14(3):e0213804. 10.1371/journal.pone.0213804 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.da Silva M, Blevins M, Wester CW, Manjolo J, José E, Gonzalez LC, et al. Patient loss to follow-up before antiretroviral therapy initiation in rural Mozambique. AIDS Behav. 2015;19(4):666–678. 10.1007/s10461-014-0874-0 [DOI] [PubMed] [Google Scholar]
  • 3.Shepherd BE, Blevins M, Vaz LM, Moon TD, Kipp AM, José E, et al. Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique. Am J Epidemiol.2013;5(178):819–828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ciampa PJ, Tique J, Juma N, Sidat M, Moon TD, Rothman RL, et al. Addressing poor retention of infants exposed to HIV: a quality improvement study in rural Mozambique. J Acquir Immune Defic Syndr.2012; 60(2):e46–52. 10.1097/QAI.0b013e31824c0267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Groh K, Audet CM, Baptista A, Sidat M, Vergara A, Vermund SH, et al. Barriers to antiretroviral therapy adherence in rural Mozambique. BMC Public Health.2011;11:650. 10.1186/1471-2458-11-650 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Moon TD, Burlison JR, Sidat M, Pires P, Silva W, Solis M, et al. Lessons learned while implementing an HIV/AIDS care and treatment program in rural Mozambique. Retrovirology Res Treat.2010;3:1–14. 10.4137/RRT.S4613 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Mugabe D, Bhatt N, Carlucci JG, Samo Gudo E, Gong W, Sidat M, et al. Self-reported non-receipt of HIV test results: A silent barrier to HIV epidemic control in Mozambique. PLoS One. 2019;14(10):e0224102. 10.1371/journal.pone.0224102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Mozambique Country Operational Plan 2019:Strategic Directional Summary PEPFAR. Available from: https://www.state.gov/wp-content/uploads/2019/09/Mozambique_COP19-Strategic-Directional-Summary_public.pdf.
  • 9.Nosyk B, Lourenço L, Min JE, Shopin D, Lima VD, Montaner JSG, et al. Characterizing retention in HAART as a recurrent event process: insights into ‘cascade churn’. AIDS.2015;29(13):1681–1689. 10.1097/QAD.0000000000000746 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fuente-Soro L, Iniesta C, López-Varela E, Cuna M, Guilaze R, Maixenchs M, et al. Tipping the balance towards long-term retention in the HIV care cascade: A mixed methods study in southern Mozambique. PLoS One. 2019;14(9):e0222028. 10.1371/journal.pone.0222028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Fuente-Soro L, López-Varela E, Augusto O, Bernardo EL, Sacoor C, Nhacolo A, et al. Loss to follow-up and opportunities for reengagement in HIV care in rural Mozambique: a prospective cohort study. Medicine. 2020;99(20):e20236. 10.1097/MD.0000000000020236 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Jobarteh K, Shiraishi RW, Malimane I, Samo Gudo P, Decroo T, Auld AF, et al. Community ART Support Groups in Mozambique: The Potential of Patients as Partners in Care. PLoS One 2016;11(12):e0166444. 10.1371/journal.pone.0166444 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Clouse K, Phillips TK, Camlin C, Noholoza S, Mogoba P, Naidoo J, et al. CareConekta: study protocol for a randomized controlled trial of a mobile health intervention to improve engagement in postpartum HIV care in South Africa. Trials.2020;21(1):258. 10.1186/s13063-020-4190-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kwena ZA, Camlin CS, Shisanya CA, Mwanzo I, Bukusi EA. Short-term mobility and the risk of HIV infection among married couples in the fishing communities along Lake Victoria, Kenya. PloS One.2013;8(1):e54523. 10.1371/journal.pone.0054523 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Marson KG, Tapia K, Kohler P, McGrath CJ, John-Stewart GC, Richardson BA, et al. Male, mobile, and moneyed: loss to follow-up vs. transfer of care in an urban African antiretroviral treatment clinic. PloS One.2013; 8(10):e78900. 10.1371/journal.pone.0078900 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bygrave H, Kranzer K, Hilderbrand K, Whittal J, Jouquet G, Goemaere E, et al. Trends in loss to follow-up among migrant workers on antiretroviral therapy in a community cohort in Lesotho. PloS One. 2010;5(10):e13198. 10.1371/journal.pone.0013198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Taylor BS, Reyes E, Levine EA, Kahn SZ, Garduño S, Donastorg Y, et al. Patterns of Geographic Mobility Predict Barriers to Engagement in HIV Care and Antiretroviral Treatment Adherence. AIDS Patient Care STDs 2014;28(6):284–295. 10.1089/apc.2014.0028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.UNAIDS and IOM sign agreement to improve access to HIV services for migrants. Available from: https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2011/january/20110121unaidsiompr.
  • 19.Camlin CS, Cassels S, Seeley J. Bringing population mobility into focus to achieve HIV prevention goals. J Int AIDS Soc.2018;21(Suppl 4):e25136. 10.1002/jia2.25136 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Faturiyele I, Karletsos D, Ntene-Sealiete K, Musekiwa A, Khabo M, Marti M, et al. Access to HIV care and treatment for migrants between Lesotho and South Africa: a mixed methods study. BMC Public Health.2018;18(1):668. 10.1186/s12889-018-5594-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.World Migration Report 2020. Available from: https://www.iom.int/wmr/.
  • 22.CISM. Health Research Center of Manhiça. Available from: http://manhica.org/wp/en/home-en/.
  • 23.Nhassengo P, Cataldo F, Magaço A, Hoffman RM, Nerua L, Saide M, et al. Barriers and facilitators to the uptake of Test and Treat in Mozambique: A qualitative study on patient and provider perceptions. PLoS One.2018;13(12):e0205919. 10.1371/journal.pone.0205919 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.National Institute of Statistics-Mozambique. Available from: http://www.ine.gov.mz/.
  • 25.Sacoor C, Nhacolo A, Nhalungo D, Aponte JJ, Bassat Q, Augusto O, et al. Profile: Manhiça Health Research Centre (Manhiça HDSS). Int J Epidemiol. 2013;42(5):1309–1318. 10.1093/ije/dyt148 [DOI] [PubMed] [Google Scholar]
  • 26.Nhacolo AQ, Nhalungo DA, Sacoor CN, Aponte JJ, Thompson R, Alonso P. Levels and trends of demographic indices in southern rural Mozambique: evidence from demographic surveillance in Manhiça district | BMC Public Health.2006;6:291. 10.1186/1471-2458-6-291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.González R, Muguambe K, Aponte JJ, Bavo C, Nhalungo D, Macete E, et al. High HIV prevalence in a southern semi-rural area of Mozambique: a community-based survey. HIV Med.2012;13(10):581–588. 10.1111/j.1468-1293.2012.01018.x [DOI] [PubMed] [Google Scholar]
  • 28.Research. Open Data Kit. Available from: https://opendatakit.org/community/research/.
  • 29.Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform.2009;42(2):377–381. 10.1016/j.jbi.2008.08.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.González R, Augusto OJ, Munguambe K, Pieratt C, Pedro EN, Sacoor C, et al. HIV Incidence and Spatial Clustering in a Rural Area of Southern Mozambique. PLoS One.2015;10(7):e0132053. 10.1371/journal.pone.0132053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Migration in Southern Africa. Global Commission on International Migration. Available from: https://www.iom.int/jahia/webdav/site/myjahiasite/shared/shared/mainsite/policy_and_research/gcim/rs/RS7.pdf.
  • 32.de Bruijn M, van Dijk RA, Foeken DWJ. Mobile Africa: Changing Patterns of Movement in Africa and Beyond. Available at: https://openaccess.leidenuniv.nl/handle/1887/21983.
  • 33.Beyond Borders: Redefining Urban Mobility in South Africa. Available from: https://space10.com/beyond-borders-mobility-in-south-africa/.
  • 34.Mozambique Country Strategy Paper 2018–2022. Available from: https://www.afdb.org/en/documents/document/mozambique-country-strategy-paper-2018-2022-103013.
  • 35.Migration and Health in South Africa. November 2010. Available from: http://www.migration.org.za/wp-content/uploads/2017/08/Migration-and-health-in-SADC-A-review-of-the-literature.pdf.
  • 36.Mozambican Ministry of Health. HIV Care and Treatment Guideline. Available from: http://www.misau.gov.mz/index.php/guioes-de-cuidados-e-tratamento#.

Decision Letter 0

Matt A Price

6 Nov 2020

PONE-D-20-25254

Patterns of mobility and its impact on retention in care among people living with HIV in the Manhiça District, Mozambique

PLOS ONE

Dear Dr. Moon,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please ensure that your decision is justified on PLOS ONE’s publication criteria and not, for example, on novelty or perceived impact.

Please submit your revised manuscript by Dec 20 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Matt A Price

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (i) whether consent was informed and (ii) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

3. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) a description of any inclusion/exclusion criteria that were applied to participant recruitment, and b) a statement as to whether your sample can be considered representative of a larger population."

4. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

5.During our internal checks, the in-house editorial staff noted that you conducted research or obtained samples in another country. Please check the relevant national regulations and laws applying to foreign researchers and state whether you obtained the required permits and approvals. Please address this in your ethics statement in both the manuscript and submission information. In addition, please ensure that you have suitably acknowledged the contributions of any local collaborators involved in this work in your authorship list and/or Acknowledgements. Authorship criteria is based on the International Committee of Medical Journal Editors (ICMJE) Uniform Requirements for Manuscripts Submitted to Biomedical Journals - for further information please see here: https://journals.plos.org/plosone/s/authorship.

6. Please provide a sample size and power calculation in the Methods, or discuss the reasons for not performing one before study initiation."

7. Please note that PLOS does not permit references to “data not shown.” Authors should provide the relevant data within the manuscript, the Supporting Information files, or in a public repository. If the data are not a core part of the research study being presented, we ask that authors remove any references to these data.

We ask that you please remove citations for unavailable and unpublished work, including manuscripts that have been submitted but not yet accepted (e.g., “unpublished work,” “data not shown”). Instead, include those data as supplementary material or deposit the data in a publicly available database.

8. Thank you for stating the following in the Acknowledgments Section of your manuscript:

'CISM is supported by the Government of Mozambique and the Spanish Agency for International Development

(AECID). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation

through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-00806-S), and

support from the Generalitat de Catalunya through the CERCA Program.'

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

'The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript'

9. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Additional Editor Comments (if provided):

[From the editor]

Methods, line 102: Please describe your statistical power to detect associations between your independent variables and your outcome of interest (retained in care, right?). With 195 persons in each comparison arm, are you well powered to see differences in retention in care, should they exist?

Methods, line 132: This is an outcome (singular) not “outcomes” (plural), right? Or am I misunderstanding something here?

Methods, line 143: “response” variables is what? The outcome (i.e., “retained in care” – one outcome variable?) Or did you also look at mobility? Also you may have gone between self report and pharmacy records; kindly make this more explicit.

Methods, line 143: do not report results in methods (i.e., move “we found no clinically or statistically significant findings” to the results section – is this what you show on line 187?)

Table 2: What is the “other” category that makes up more than two thirds of those didn’t/couldn’t get ART at travel destination? Is it for the reasons explained in the text? Consider adding this as a footer, or making more table rows to clarify.

Line 187 (and stat analysis in methods): is your multivariable analysis have “retention in care” as the outcome, or “self-reported perceived challenges in accessing HIV care”? Or both? Please clarify this in the methods, and do show these results, as no difference (assuming you have power to detect a difference should one exist) is an important result for all these analyses you may be doing.

Results, line 193: What’s the difference between “Most (45%), stated they would prefer a 3 to 6-month dosing schedule, followed by a 3-month dosing schedule (33%),”? These two responses seem to overlap/ include each other, making interpretation of this response challenging.

Line 201+ and Table 4: I am confused about this outcome. Why is the N for Table 4 only 349? I recommend considering a trichotomous outcome regarding retention in care: 1) retained in care, 2) Delayed ART pickups (15-60 days late) and 3) Lost to follow-up (>60 days) so that the entire cohort can be analyzed together. You are further impacting your statistical power by slicing up your study this way.

Table 4: If there is missing data (i.e., 349 vs. 390) please explain and show this so the reader can understand what’s missing and where.

Line 204: I am confused by your statement “This represents just 3% of our total population self-reporting they had ever been lost to follow-up (data not shown).” In table 4, it looks like you are showing the data: 37 report ever being lost to follow up, or 11% of the reduced cohort shown. This section is hard to follow, please revisit.

Discussion: please make note of how well powered your study was to detect a difference in your outcome (outcomes?), particularly in light of the fact that it appears your analysis was affected by missing data (e.g., Table 4 is not n=390)

Line 245: “However, what is striking is the large disparity between what we could document based on pharmacy pick-up records and the participants self-reported perception of their ever being lost to follow-up.” Did I miss this? Where in your results do you present this disparity? This seems like an important piece of data to show. This seems like an important data point to add, perhaps to Table 4. How did this outcome vary between self-report and pharmacy records, and how did this vary across study group (mobile, not-mobile).

Line 271: Kindly remind the reader that the aforementioned study (studies? Several references are listed) are from Lesotho as the next sentence otherwise is a bit confusing.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Feedback to the authors

Major points

Abstract

Some important methodological details are not mentioned: self-reported interview data from mobile and non-mobile patients on ART care were compared with ART uptake data from clinical records, but the former comprised data from 390 participants whilst the latter was only available for 349 of these, thus possibly inviting selection bias. This fact is neither mentioned in the Abstract, nor the limitation discussed.

Methods

1. The statement that ‘consecutive’ patients were enrolled cannot be quite correct, given the matching process used. Please clarify whether all patients reporting to be mobile were consecutively enrolled. Regarding the matched non-mobile participants, please clarify whether they were selected from all those who met the matching criteria and presented to the clinic during the next 7 days. In other words, was the research assistant free to chose a patient who he/she preferred out of all possible matches, thus possibly inviting further selection bias, or was there a systematic rule for the selection that was followed?

2. As mentioned for the Abstract, in the section on Data collection the information is missing that clinical records were only available from subset of 349 of the 390 participants! This needs to be explicitly stated here or latest in the Results section; and an explanation provided on why this difference occurred. This is a limitation that should also be addressed in the Discussion.

3. The definition used for ‘delayed ART pick-ups’ (defined as gaps of more than 15 days after scheduled refills, see line 135) is rather inaccurate and broad, given that viral resistance often develops after much shorter interruptions in adherence. It would be helpful if the authors had studied whether a more stringent definition may be associated with a difference between mobile and non-mobile subgroups with respect to ART uptake.

Results

1. Some key information is missing that is required to understand the context: what is the total number of ART receiving patients registered at the Manhiça District Hospital from where the study population was selected (and of these what is the proportion of patients that achieved viral control at the time of the study)?

2. What are the proportions of study participants in the two comparison groups of this study who were virally controlled at their last visit? Was there a significant difference between study groups in this respect? Data on viral control were available at the time in a data set from another province of Mozambique that I have recently seen, but if such data were not available from the Manhiça HIV care centre at the time, what were the proportions of study participants in the two groups that had a satisfactory CD4 count (say e.g. >200 cells/mm3), and did this differ between study groups? This information would be important to assess the effects of mobility on retention in ART care, and would substantially increase the value of this publication. If no such data were available at all, this would at the very least require mention in the Discussion section.

3. Unfortunately there are many missing data without that this is explicitly stated (and without that the possible implications for the validity of the results are explored in the Discussion section). Examples include the following: (1) In Table 1, I was puzzled to realise that data on age was only available from 328 of 390 participants (16% missing!). How was it possible then to ‘match on age’? - (2) 23% of data were missing for ‘employment’, yet employment features as a key variable in the consecutive analysis. – (3) The one and only clinical information that related to clinical severity was WHO stage, however again data were missing for 33/390 participants (8%). Note that data on clinical severity may well be associated with ART uptake. – (4) Importantly as mentioned, data on ART uptake were missing for 41/390 participants (11%) from the hospital-based data set (Table 4). Further examples of missing data can be found in tables 2 and 3. With so many data missing, one wonders how valid are the results presented? The authors should at least indicate missing data in footnotes to the various tables, mention the more important data gaps when reporting results in the text, and reflect on this issue in the Discussion section.

4. In some cases, reported data do not tally within tables, or between tables and the text. Some examples: Table 1: employment data are 298, but 299 under ‘type of employment’. Table 2: 147 people travelled for work, but 148 of these gave information on what work they did. Also Table 2: 53 / 195 people travelled within the country (27%), but 25% are mentioned in the relevant text.

Discussion

The text is generally well written but the limitations described above (e.g. due to methodological issues and missing data) should be addressed.

Conclusion

The Conclusion section is misleading. It focuses on mobile HIV patients and the challenges that they encounter with respect to HIV care when they travel. This ignores that for the patients registered at the Manhiça Hospital the results underlying these conclusions seem to equally apply to the non-mobile group of patients. In fact, the lack of significant differences between the mobile and non-mobile groups with regards to ART uptake is surprising and should be mentioned as an important result in the Conclusion. The real conclusion should refer to the rather worrying lack of adherence in ART uptake that affects both groups.

General observations

The paper could be substantially shortened by condensing the text. Repeat statements should be deleted (e.g. see lines 262 and 277).

Minor points

1. Please use past tense consistently across the manuscript. (Occasionally the text alternates between past and present tense).

2. Some phrases are long-winded and could be compressed to just entail the essential information.

Methods

3. The section on data collection and management is NOT about data analysis as suggested by its headline.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 May 21;16(5):e0250844. doi: 10.1371/journal.pone.0250844.r002

Author response to Decision Letter 0


30 Mar 2021

please see uploaded document with our response to reviewers

1) Thank you for updating your Data Availability Statement as follows:

"The data underlying the results presented in the study are available here and from the Manhiça Health Research Center by request to Tacilta Nhampossa at tacilta.nhampossa@manhica.net"

-We also note your following additional comments:

"We have provided a de-identified data set to accompany this manuscript as supporting information."

1.1.) Please confirm whether the minimal data set is located in your manuscript and/or Supporting Information files.

1.2.) If the minimal data set is located in your manuscript and/or Supporting Information files, please confirm whether we may update your Data Availability Statement as follows:

“All relevant data are within the manuscript and its Supporting Information files.”

Response: I confirm the data set is located in the manuscript and the data availability statement can be updated as proposed: “All relevant data are within the manuscript and its Supporting Information files.”

2) We note that you have replaced your Figure 1 map.

Before we can proceed, please clarify where the authors obtained the replacement map for Figure 1.

Response: We accessed a free generic map of Mozambique at https://map.comersis.com/Mozambique-maps-MZ.html and then the authors edited it to meet the needs of the figure for this publication.

3) Thank you for providing the following response in your cover letter: "I am confused about your recent comment about funding. In the most recent versions submitted all reference to funding had already been removed from the acknowledgement section.

Please update the funding statement to the following:

This research was supported by the Fogarty International Center of the National Institutes of Health under Award Number D43 TW009745. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. 'The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript"

Response: we confirm that the above is the funding statement as we would like it to be associated with this manuscript

Thank you as well for removing the following information from your Acknowledgements section: "CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-00806-S), and support from the Generalitat de Catalunya through the CERCA Program."

However, before we proceed with updating your Financial Disclosure statement as requested, please clarify the following:

3.1. Who or what is meant by "CISM" and "ISGlobal"?

3.2. Were any authors of the study supported by the following: the Government of Mozambique and the Spanish Agency for International Development (AECID); the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-00806-S); the Generalitat de Catalunya through the CERCA Program?

If so, please provide the names of each author specifically associated with each funding source, as well as any relevant grant numbers associated with "the Generalitat de Catalunya through the CERCA Program".

3.3. Please clarify why the following information was omitted from your updated Financial Disclosure statement: "CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-00806-S), and support from the Generalitat de Catalunya through the CERCA Program."

This information will be helpful in updating your funding statements.

Response: we apologize but there was initially confusion amongst the authors as to what constituted financial support for the work presented here. We have removed the above-mentioned reference because, while yes, they are funding or affiliations associated with either the institutions or individuals involved in this work, they did not specifically contribute to the work performed here in this manuscript.

CISM is an acronym meaning Centro de Investigação em Saúde de Manhiça or Manhiça Health Research Center and it is affiliated with both the Government of Mozambique and the Spanish Agency for International Development (AECID), however neither directly funded this research project.

ISGlobal is the common name for the Barcelona Institute for Global Health, of which authors Fernández-Luis, Fuente-Soro and Naniche are affiliated. While yes, ISGlobal receives funding from the Spanish Ministry of Science and Innovation through the programs listed above, those programs should not have been referenced as funding the research presented here in this manuscript.

We again apologize for the confusion created, if any, but those statements should be removed.

Attachment

Submitted filename: Response to Reviewers_final.pdf

Decision Letter 1

Matt A Price

15 Apr 2021

Patterns of mobility and its impact on retention in care among people living with HIV in the Manhiça District, Mozambique

PONE-D-20-25254R1

Dear Dr. Moon,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Matt A Price

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Matt A Price

14 May 2021

PONE-D-20-25254R1

Patterns of mobility and its impact on retention in care among people living with HIV in the Manhiça District, Mozambique

Dear Dr. Moon:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Matt A Price

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Study survey mobile adult english.

    (DOCX)

    S2 File. Study survey mobile adult portuguese.

    (DOCX)

    S3 File. Study survey nonmobile adult english.

    (DOCX)

    S4 File. Study survey nonmobile adult portuguese.

    (DOCX)

    S5 File. Deidentified data set.

    (XLSX)

    S6 File. Data dictionary for deidentified data set.

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers_final.pdf

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES